Atorvastatin
ATC C10AA05 · WHO DDD 20 mg (oral) · 20 mg tablet
Class: Lipid-modifying agents. ATC code C10AA05 stands for "atorvastatin" in the WHO index, whose DDD is 20 mg by the oral route [1].
WHO Model List of Essential Medicines 2025: listed, core list [2].
Indications on the WHO list (2)
- Mixed hyperlipidaemia · core list · therapeutic equivalent of simvastatin · 12. Cardiovascular medicines 12.6. Lipid-lowering agents · first added 2007
- Coronary atherosclerosis · core list · therapeutic equivalent of simvastatin · 12. Cardiovascular medicines 12.6. Lipid-lowering agents · first added 2007
The WHO electronic list states that the 2025 PDF lists are binding: adults’ list, children’s list.
| Country | Packs | Kind of figure | Cost per DDD | Annual cost at the WHO standard dose |
|---|---|---|---|---|
| France | 32 | List price | €0.13 to €0.16 | €47.86 to €59.05 |
| Spain | 46 | List price | €0.26 | €93.86 |
| United Kingdom | 1 | Reimbursement tariff | €0.04 | €12.76 £10.82 |
Names, authorisations and literature
Trade names (50)
- France (14)
- ATORVASTATINE ALMUS PHARMA, ATORVASTATINE ARROW GENERIQUES, ATORVASTATINE BIOGARAN, ATORVASTATINE CRISTERS PHARMA, ATORVASTATINE EG LABO, ATORVASTATINE EVOLUGEN, ATORVASTATINE HCS, ATORVASTATINE SANDOZ, ATORVASTATINE TEVA, ATORVASTATINE VIATRIS SANTE, ATORVASTATINE ZENTIVA, ATORVASTATINE ZYDUS, ATORVASTATINE ZYDUS FRANCE, TAHOR [4]
- Spain (36)
- ATORIS, ATORVASTATINA ABEX, ATORVASTATINA ALMUS PHARMA, ATORVASTATINA ALTER GENERICOS, ATORVASTATINA AUROVITAS PHARMA, ATORVASTATINA BLUEFISH, ATORVASTATINA CINFA, ATORVASTATINA COMBIX, ATORVASTATINA COMBIX PHARMA, ATORVASTATINA DAVURGAMA, ATORVASTATINA FARMA-MABO, ATORVASTATINA KERN PHARMA, ATORVASTATINA KRKA, ATORVASTATINA MABO, ATORVASTATINA NORMOGEN, ATORVASTATINA NORMON, ATORVASTATINA OPKO, ATORVASTATINA PENSA PHARMA, ATORVASTATINA PHARMA COMBIX, ATORVASTATINA QUALIGEN FARMA, ATORVASTATINA QUALIGEN PHARMA, ATORVASTATINA SANDOZ, ATORVASTATINA STADAGEN, ATORVASTATINA SUN, ATORVASTATINA TARBIS, ATORVASTATINA TARBIS FARMA, ATORVASTATINA TECNIGEN, ATORVASTATINA TEVA-RATIO, ATORVASTATINA VIATRIS, ATORVASTATINA VIR PHARMA, ATORVASTATINA ZENTIVA LAB, ATORVATATINA TECNIGEN, CARDYL, PREVENCOR, THERVAN, ZARATOR [5]
Links lead to the official product page: the EPAR for the European Union, the public medicines database for France, the CIMA summary of product characteristics for Spain, the dm+d for the United Kingdom. An asterisk marks a name taken from the DysNet register only.
European public assessment reports, EPAR (0)
The European Medicines Agency's list holds no medicine with ATC code C10AA05: this medicine has no EPAR [6].
Literature (PubMed, 13,093 papers)
PubMed counts 13,093 papers on this medicine [7]. The selection gives the most recent of each type; the Method page says how it is made. See the search in PubMed ↗
Cochrane reviews (28)
- Senior HE, et al. Interventions for fatigue management after traumatic brain injury. Cochrane Database Syst Rev. 2026. PubMed 41700575 ↗ doi ↗
- Wang Z, et al. Statins for the primary prevention of venous thromboembolism. Cochrane Database Syst Rev. 2024. PubMed 39498835 ↗ doi ↗
- Adams SP, et al. Pravastatin for lowering lipids. Cochrane Database Syst Rev. 2023. PubMed 37721222 ↗ doi ↗
- Clezar CN, et al. Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database Syst Rev. 2023. PubMed 37565307 ↗ doi ↗
- Xiong T, et al. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev. 2023. PubMed 37462232 ↗ doi ↗
Systematic reviews and meta-analyses (370)
- Lin X, et al. Efficacy and safety of PCSK9 inhibitors combined with statins in acute ischemic stroke: a systematic review and meta-analysis. J Neurol. 2026. PubMed 42848227 ↗ doi ↗
- Huino SV, et al. The effect of anti-seizure medications on exposure to statins: A systematic review and meta-analysis. Epileptic Disord. 2026. PubMed 42828464 ↗ doi ↗
- Sanikommu S, et al. Impact of Modifiable Cardiovascular Risk Factors and Protective Therapies on Hemorrhagic Events in Cerebral Cavernous Malformations: A Systematic Review and Meta-Analysis. Brain Behav. 2026. PubMed 42851022 ↗ doi ↗
- Cueva-Cañola LE, et al. Comparative efficacy and safety of rosuvastatin versus atorvastatin after acute ischemic stroke or transient ischemic attack: A systematic review and exploratory meta-analysis. Med Clin (Barc). 2026. PubMed 42636678 ↗ doi ↗
- Omayer A, et al. Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord. 2026. PubMed 42723012 ↗ doi ↗
Practice guidelines (6)
- Wolthuis DFGJ, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. Eur J Hum Genet. 2025. PubMed 39676086 ↗ doi ↗
- Cooper-DeHoff RM, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022. PubMed 35152405 ↗ doi ↗
- Lipid-lowering drugs. Med Lett Drugs Ther. 2019. PubMed 30845106 ↗
Health technology assessments (6)
The opinions of the assessment bodies of the pilot countries and of Germany, with a link to each opinion. The status shown is the one each body publishes.
France, HAS Transparency Committee (4)
SMR: actual clinical benefit. ASMR: improvement in actual clinical benefit, from I (major) to V (none). Opinions taken from the BDPM [4].
- CT-14780 · 17 February 2016 · Renouvellement d'inscription (CT) · SMR Important · TAHOR
Wording of the opinion, in French
SMR : Le service médical rendu par TAHOR reste important dans les indications de l’AMM.
- CT-12516 · 21 November 2012 · Extension d'indication · ASMR V · TAHOR
Wording of the opinion, in French
ASMR : Chez les enfants et adolescents de 10 à 17 ans avec hypercholestérolémie familiale hétérozygote ou dyslipidémie mixte, TAHOR n’apporte pas d’amélioration du service médicale rendu (ASMR V) par rapport aux alternatives disponibles (pravastatine, rosuvastatine).
- CT-12515 · 21 November 2012 · Inscription (CT) · ASMR V · TAHOR
Wording of the opinion, in French
ASMR : Ces spécialités sont des compléments de gamme qui n’apportent pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres formes galéniques et présentations déjà inscrites.
- CT-2034 · 4 January 2006 · Extension d'indication · ASMR I, V · TAHOR
Wording of the opinion, in French
ASMR : Dans l'extension d’indication Prévention des événements coronaires et cérébrovasculaires chez des patients diabétiques de type 2 avec un autre facteur de risque, avec ou sans hyperlipidémie associée, l’atorvastatine à la posologie de 10 mg/j partage avec la simvastatine 40 mg/j la même amélioration du service médical rendu : amélioration du service médical rendu majeure (ASMR I), en prévention secondaire chez des patients avec des antécédents d’AVC ou souffrant d’artériopathie périphérique, sans hyperlipidémie, et en prévention primaire chez les diabétiques de type 2 ayant un risque cardio-vasculaire élevé, indépendamment de la cholestérolémie.
ASMR : Dans l'extension d’indication Prévention des événements coronaires et cérébrovasculaires chez des patients diabétiques de type 2 avec un autre facteur de risque, avec ou sans hyperlipidémie associée, l’atorvastatine à la posologie de 10 mg/j partage avec la simvastatine 40 mg/j la même amélioration du service médical rendu : pas d'amélioration du service médical rendu majeure (ASMR V), chez le coronarien, indépendamment du niveau du cholestérol.
England, NICE (0)
NICE has published no technology appraisal that names this medicine among the technologies appraised [8].
Scotland, SMC (2)
- SMC 766/12 · 12 March 2012 · atorvastatin (Lipitor) · accepted · Abbreviated
Indication
Chewable tablets which have been developed for the treatment of hypercholesterolaemia in adolescents and children aged 10 years or older.
- SMC 202/05 · 10 October 2005 · Atorvastatin (Lipitor®) · restricted · Abbreviated
Indication
Reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholeste
- SMC advice [9]
Germany, G-BA (0)
The G-BA has run no early benefit assessment (AMNOG) of this medicine on its own [10].
Spain, AEMPS therapeutic positioning reports (0)
The AEMPS database of therapeutic positioning reports holds no report on this medicine [11].
How the figure is computed
Example, France: the pack ATORVASTATINE TEVA 20 mg, comprimé pelliculé sécable, 90 plaquettes prédécoupées unitaires polyamide aluminium PVC-Aluminium de 1 comprimé, costs €11.80. It holds 1,800 mg, which is 90 DDD. The cost per DDD is €11.80 ÷ 90 = €0.13, and the annual cost at the WHO standard dose, list price, is that cost × 365 = €47.86.
France
Public price in France, including VAT and the per-pack dispensing fee. Source [4], read on 9 October 2026. ATC match: through the active substance (BDPM substance code), since the BDPM gives no ATC code.
Show the 32 packs
| Product | Pack | Price | DDD per pack | Cost per DDD | Annual cost at the WHO standard dose | Source line |
|---|---|---|---|---|---|---|
| ATORVASTATINE TEVA 20 mg, comprimé pelliculé sécableTEVA (PAYS-BAS) | 90 plaquettes prédécoupées unitaires polyamide aluminium PVC-Aluminium de 1 comprimé | €11.80 | 90 | €0.13 | €47.86 | CIS 60874050 / CIP13 3400930305454substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE VIATRIS SANTE 20 mg, comprimé pelliculé sécableVIATRIS SANTE | plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 61310519 / CIP13 3400930330531substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE EVOLUGEN 20 mg, comprimé pelliculéEVOLUPHARM | plaquette(s) aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 61391955 / CIP13 3400930211045substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZENTIVA 20 mg, comprimé pelliculéZENTIVA FRANCE | plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 61482159 / CIP13 3400930124406substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE EG LABO 20 mg, comprimé pelliculéEG LABO - LABORATOIRES EUROGENERICS | plaquette(s) OPA : polyamide orienté aluminium PVC de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 61805662 / CIP13 3400930050019substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZYDUS FRANCE 20 mg, comprimé pelliculéZYDUS FRANCE | plaquette(s) thermoformée(s) aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 62864852 / CIP13 3400922190624substance code 50091 (ATORVASTATINE CALCIQUE) in CIS_COMPO_bdpm |
| ATORVASTATINE HCS 20 mg, comprimé pelliculéHCS (BELGIQUE) | plaquette(s) polyamide aluminium PVC-Aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 64176801 / CIP13 3400926634896substance code 50091 (ATORVASTATINE CALCIQUE) in CIS_COMPO_bdpm |
| ATORVASTATINE ALMUS PHARMA 20 mg, comprimé pelliculéALMUS FRANCE | plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 64308092 / CIP13 3400930169896substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZYDUS 20 mg, comprimé pelliculéZYDUS FRANCE | plaquette(s) formée(s) à froid OPA : polyamide orienté aluminium PVC-Aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 64572537 / CIP13 3400930145357substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE SANDOZ 20 mg, comprimé pelliculé sécableSANDOZ | plaquette(s) aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 67762488 / CIP13 3400941531897substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE BIOGARAN 20 mg, comprimé pelliculéBIOGARAN | plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 68212077 / CIP13 3400930183076substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE CRISTERS PHARMA 20 mg, comprimé pelliculéCRISTERS | plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 68666845 / CIP13 3400930197059substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ARROW GENERIQUES 20 mg, comprimé pelliculéARROW GENERIQUES | plaquette(s) polyamide aluminium PVC-Aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 69068936 / CIP13 3400930035405substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ARROW GENERIQUES 20 mg, comprimé pelliculéARROW GENERIQUES | plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) | €11.80 | 90 | €0.13 | €47.86 | CIS 69068936 / CIP13 3400930178157substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE TEVA 20 mg, comprimé pelliculé sécableTEVA (PAYS-BAS) | 30 plaquettes prédécoupées unitaires polyamide aluminium PVC-Aluminium de 1 comprimé | €4.20 | 30 | €0.14 | €51.10 | CIS 60874050 / CIP13 3400930305447substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE VIATRIS SANTE 20 mg, comprimé pelliculé sécableVIATRIS SANTE | plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 61310519 / CIP13 3400930263495substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE VIATRIS SANTE 20 mg, comprimé pelliculé sécableVIATRIS SANTE | 1 flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 61310519 / CIP13 3400930330562substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE EVOLUGEN 20 mg, comprimé pelliculéEVOLUPHARM | plaquette(s) aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 61391955 / CIP13 3400930211014substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZENTIVA 20 mg, comprimé pelliculéZENTIVA FRANCE | plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 61482159 / CIP13 3400930124369substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE EG LABO 20 mg, comprimé pelliculéEG LABO - LABORATOIRES EUROGENERICS | plaquette(s) OPA : polyamide orienté aluminium PVC de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 61805662 / CIP13 3400930049976substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZYDUS FRANCE 20 mg, comprimé pelliculéZYDUS FRANCE | plaquette(s) thermoformée(s) aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 62864852 / CIP13 3400949395019substance code 50091 (ATORVASTATINE CALCIQUE) in CIS_COMPO_bdpm |
| ATORVASTATINE HCS 20 mg, comprimé pelliculéHCS (BELGIQUE) | plaquette(s) polyamide aluminium PVC-Aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 64176801 / CIP13 3400926634377substance code 50091 (ATORVASTATINE CALCIQUE) in CIS_COMPO_bdpm |
| ATORVASTATINE ALMUS PHARMA 20 mg, comprimé pelliculéALMUS FRANCE | plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 64308092 / CIP13 3400930169889substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ZYDUS 20 mg, comprimé pelliculéZYDUS FRANCE | plaquette(s) formée(s) à froid OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 64572537 / CIP13 3400930145326substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE SANDOZ 20 mg, comprimé pelliculé sécableSANDOZ | plaquette(s) aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 67762488 / CIP13 3400941531668substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE BIOGARAN 20 mg, comprimé pelliculéBIOGARAN | plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 68212077 / CIP13 3400930183052substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE BIOGARAN 20 mg, comprimé pelliculéBIOGARAN | flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 68212077 / CIP13 3400930224632substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE CRISTERS PHARMA 20 mg, comprimé pelliculéCRISTERS | plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 68666845 / CIP13 3400930197011substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ARROW GENERIQUES 20 mg, comprimé pelliculéARROW GENERIQUES | flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 69068936 / CIP13 3400930035436substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| ATORVASTATINE ARROW GENERIQUES 20 mg, comprimé pelliculéARROW GENERIQUES | plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) | €4.20 | 30 | €0.14 | €51.10 | CIS 69068936 / CIP13 3400930178140substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| TAHOR 20 mg, comprimé pelliculéVIATRIS UP | plaquette(s) polyamide aluminium PVC-Aluminium de 90 comprimé(s) | €13.58 | 90 | €0.15 | €55.07 | CIS 69902323 / CIP13 3400937199384substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
| TAHOR 20 mg, comprimé pelliculéVIATRIS UP | plaquette(s) polyamide aluminium PVC-Aluminium de 28 comprimé(s) | €4.53 | 28 | €0.16 | €59.05 | CIS 69902323 / CIP13 3400934306815substance code 92464 (ATORVASTATINE CALCIQUE TRIHYDRATÉE) in CIS_COMPO_bdpm |
Spain
Retail price including VAT (PVP IVA). Source [12][5], read on 9 October 2026. ATC match: ATC code of each national code, checked in CIMA.
Show the 46 packs
| Product | Pack | Price | DDD per pack | Cost per DDD | Annual cost at the WHO standard dose | Source line |
|---|---|---|---|---|---|---|
| ATORVASTATINA CINFA 20 mg comprimidos recubiertos con pelicula , 28 comprimidosCINFA S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 651076AEMPS CIMA, registration 69536 |
| ATORVATATINA TECNIGEN 20 mg comprimidos recubiertos con pelicula , 28 comprimidosTECNIMEDE ESPAÑA INDUSTRIA FARMACEUTICA S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 660309AEMPS CIMA, registration 69498 |
| ATORVASTATINA VIR PHARMA 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosINDUSTRIA QUIMICA Y FARMACEUTICA VIR, S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 665535AEMPS CIMA, registration 72441 |
| PREVENCOR 20MG 28 COMPRIMIDOS RECUBIERTOSVIATRIS PHARMACEUTICALS, S.L. | 28 COMPRIMIDOS | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 667469AEMPS CIMA, registration 61743 |
| CARDYL 20MG 28 COMPRIMIDOS RECUBIERTOSVIATRIS PHARMACEUTICALS, S.L. | 28 COMPRIMIDOS | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 667873AEMPS CIMA, registration 61717 |
| ZARATOR 20MG 28 COMPRIMIDOS RECUBIERTOSVIATRIS PHARMACEUTICALS, S.L. | 28 COMPRIMIDOS | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 669069AEMPS CIMA, registration 61655 |
| ATORVASTATINA MABO 20 mg comprimidos recubiertos con pelicula , 28 comprimidosMABO-FARMA, S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 673035AEMPS CIMA, registration 72282 |
| ATORIS 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA , 28 comprimidosKRKA D.D. NOVO MESTO | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 675974AEMPS CIMA, registration 71718 |
| ATORVASTATINA KRKA 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosKRKA D.D. NOVO MESTO | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 676461AEMPS CIMA, registration 73176 |
| ATORVASTATINA COMBIX 20 mg comprimidos recubiertos con pelicula , 28 comprimidosCOMBIX, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 677358AEMPS CIMA, registration 73776 |
| ATORVASTATINA TARBIS 20 mg comprimidos recubiertos con pelicula , 28 comprimidosTARBIS FARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 679404AEMPS CIMA, registration 73828 |
| ATORVASTATINA SUN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosSUN PHARMA LABORATORIOS, S.L | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 693349AEMPS CIMA, registration 76534 |
| ATORVASTATINA VIATRIS 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosVIATRIS PHARMACEUTICALS, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 693688AEMPS CIMA, registration 73731 |
| ATORVASTATINA PHARMA COMBIX 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosCOMBIX, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 700797AEMPS CIMA, registration 78279 |
| ATORVASTATINA ZENTIVA LAB 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosZENTIVA KS | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 705217AEMPS CIMA, registration 79531 |
| ATORVASTATINA STADAGEN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG , 28 comprimidosSTADA, S.L | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 710309AEMPS CIMA, registration 80729 |
| ATORVASTATINA ABEX 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosKERN PHARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 719767AEMPS CIMA, registration 82602 |
| ATORVASTATINA ALMUS PHARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosALMUS FARMACEUTICA, S.A.U. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 719811AEMPS CIMA, registration 82628 |
| ATORVASTATINA QUALIGEN FARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidos (Blister PVC/PVDC-Al)NEURAXPHARM SPAIN, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 720827AEMPS CIMA, registration 82891 |
| ATORVASTATINA STADAGEN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG 28 comprimidos (PVC-PE-PVDC-AL)STADA, S.L | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 724308AEMPS CIMA, registration 81999 |
| ATORVASTATINA AUROVITAS PHARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG,28 comprimidos (PVC/PE/PVDC-AL)AUROVITAS SPAIN, S.A.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 725298AEMPS CIMA, registration 81540 |
| ATORVASTATINA FARMA-MABO 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG. 28 comprimidosMABO-FARMA, S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 727336AEMPS CIMA, registration 84637 |
| CARDYL 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosDIFARMED, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 729191AEMPS CIMA, registration LT-1-98-3805-025 |
| ZARATOR 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosDIFARMED, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 729193AEMPS CIMA, registration LT-1-98-3805-025IP |
| ATORVASTATINA KERN PHARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosKERN PHARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 729246AEMPS CIMA, registration 85405 |
| CARDYL 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosMELYFARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 729375AEMPS CIMA, registration LT-1-98-3805-025_IP |
| ATORVASTATINA ALTER GENERICOS 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidos (PVC/PVDC/PVC-Aluminio)ALTER S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 730782AEMPS CIMA, registration 85905 |
| THERVAN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG 28 comprimidos (PVC/PVDC/PVC-Aluminio)ALTER S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 730842AEMPS CIMA, registration 85926 |
| ATORVASTATINA BLUEFISH 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosBLUEFISH PHARMA, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 731651AEMPS CIMA, registration 86210 |
| ATORVASTATINA TARBIS FARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosTARBIS FARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 732500AEMPS CIMA, registration 86452 |
| ATORVASTATINA SANDOZ 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosSANDOZ FARMACEUTICA, S.A | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 732923AEMPS CIMA, registration 86613 |
| ATORVASTATINA NORMOGEN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosNORMON S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 734044AEMPS CIMA, registration 86795 |
| ATORVASTATINA NORMOGEN 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosNORMON S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 734045AEMPS CIMA, registration 86795 |
| ATORVASTATINA PENSA PHARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosTOWA PHARMACEUTICAL, S.A. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 763324AEMPS CIMA, registration 89025 |
| ATORIS 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosDIFARMED, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 763625AEMPS CIMA, registration 776720150114 |
| ZARATOR 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosMELYFARMA, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 764611AEMPS CIMA, registration 983805025IP |
| CARDYL 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosDIFARMED, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 765630AEMPS CIMA, registration PA23055017002 |
| CARDYL 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosELAM PHARMA LABS, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 765851AEMPS CIMA, registration LT1983805025IP1 |
| CARDYL 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosECOFAR PRODUCTOS, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 766066AEMPS CIMA, registration LT1983805025IP2 |
| ATORVASTATINA TEVA-RATIO 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidos (BLISTER)TEVA PHARMA, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 766124AEMPS CIMA, registration 89923 |
| ATORVASTATINA TEVA-RATIO 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidos (FRASCO)TEVA PHARMA, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 766125AEMPS CIMA, registration 89923 |
| ATORVASTATINA DAVURGAMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosTEVA PHARMA, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 766197AEMPS CIMA, registration 89941 |
| ZARATOR 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosELAM PHARMA LABS, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 766688AEMPS CIMA, registration 1983805025IP1 |
| ATORVASTATINA COMBIX PHARMA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 comprimidosCOMBIX, S.L.U | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 767015AEMPS CIMA, registration 90165 |
| CARDYL 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosABACUS MEDICINE A/S | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 769496AEMPS CIMA, registration LT1983805025IP3 |
| CARDYL 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, 28 comprimidosEUROMED PHARMA SPAIN, S.L. | 28 comprimidos | €7.20 | 28 | €0.26 | €93.86 | Código Nacional 769847AEMPS CIMA, registration LT1983805025IP4 |
United Kingdom
Drug Tariff basic price paid to the pharmacy, excluding VAT (Part VIIIA Category M). Source [13][14], read on 9 October 2026. ATC match: ATC code of the virtual product (VMP) in the dm+d.
Show the 1 pack
| Product | Pack | Price | DDD per pack | Cost per DDD | Annual cost at the WHO standard dose | Source line |
|---|---|---|---|---|---|---|
| Atorvastatin 20mg tablets | 28 tablet | £0.83 | 28 | £0.03 | £10.82€12.76 | VMPP SNOMED 1271511000001104dm+d browser, VMP 21 |
References
- WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2026 [Internet]. Oslo: Norwegian Institute of Public Health; [updated 2026 Jan 20; cited 2026 Oct 9]. Available from: https://atcddd.fhi.no/atc_ddd_index/
- World Health Organization. Electronic Essential Medicines List (eEML) [Internet]. Geneva: WHO; [cited 2026 Oct 9]. Available from: https://list.essentialmeds.org/
- European Central Bank. Euro foreign exchange reference rates, 9 October 2026 [Internet]. Frankfurt am Main: ECB; 2026 [cited 2026 Oct 9]. Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html
- Base de données publique des médicaments [Internet]. Paris: Ministère du Travail, de la Santé, des Solidarités et des Familles; 2026 [updated 2026 Oct 8; cited 2026 Oct 9]. Available from: https://base-donnees-publique.medicaments.gouv.fr/telechargement
- Agencia Española de Medicamentos y Productos Sanitarios. CIMA: Centro de información de medicamentos [Internet]. Madrid: AEMPS; [cited 2026 Oct 9]. Available from: https://cima.aemps.es/cima/
- European Medicines Agency. Download medicine data [Internet]. Amsterdam: EMA; 2026 [updated 2026 Oct 9; cited 2026 Oct 9]. Available from: https://www.ema.europa.eu/en/medicines/download-medicine-data
- PubMed [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2026 Oct 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/
- National Institute for Health and Care Excellence. Technology appraisal guidance [Internet]. London: NICE; [cited 2026 Oct 9]. Available from: https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance
- Scottish Medicines Consortium. Medicines advice [Internet]. Glasgow: SMC; [cited 2026 Oct 9]. Available from: https://scottishmedicines.org.uk/medicines-advice/
- Gemeinsamer Bundesausschuss. Nutzenbewertung nach § 35a SGB V: Apixaban [Internet]. Berlin: G-BA; [cited 2026 Oct 9]. Available from: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/
- Agencia Española de Medicamentos y Productos Sanitarios. Informes de posicionamiento terapéutico [Internet]. Madrid: AEMPS; [cited 2026 Oct 9]. Available from: https://www.aemps.gob.es/medicamentos-de-uso-humano/evaluacion-de-tecnologias-sanitarias/informes-de-posicionamiento-terapeutico/
- Ministerio de Sanidad. Nomenclátor de facturación de octubre 2026 [Internet]. Madrid: Ministerio de Sanidad; 2026 [cited 2026 Oct 9]. Available from: https://www.sanidad.gob.es/profesionales/nomenclator.do
- NHS Business Services Authority. Drug Tariff Part VIIIA, October 2026 [Internet]. Newcastle upon Tyne: NHSBSA; 2026 [cited 2026 Oct 9]. Available from: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-part-viii
- NHS Business Services Authority. dm+d browser: NHS dictionary of medicines and devices [Internet]. Newcastle upon Tyne: NHSBSA; [updated 2026 Oct 1; cited 2026 Oct 9]. Available from: https://dmd-browser.nhsbsa.nhs.uk/